Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.64 |
| ▸ | RET | P07949 | 4/20 | 0.61 |
| ▸ | ME2 | P23368 | 1/20 | 0.55 |
| ▸ | ME1 | P48163 | 1/20 | 0.55 |
| ▸ | ME3 | Q16798 | 1/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | CKS1B | P61024 | 1/20 | 0.50 |
| ▸ | SKP1 | P63208 | 1/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109108 | 0.90 | GPR119 (0.65) | GPR119RETME2ME1ME3 | |
| SCHEMBL16473496 | 0.87 | GPR119 (0.64) | GPR119RETME2ME1ME3 | |
| SCHEMBL30906326 | 0.87 | GPR119 (0.62) | GPR119RETDDB1CRBNMAP4K4 | |
| SCHEMBL17107380 | 0.87 | GPR119 (0.62) | GPR119RETME2ME1ME3 | |
| SCHEMBL31287119 | 0.85 | GPR119 (0.65) | GPR119RETDDB1CRBNMAP4K4 | |
| SCHEMBL22638144 | 0.84 | ME2 (0.60) | GPR119RETME2ME1ME3 | |
| SCHEMBL21659187 | 0.83 | MAPT (0.60) | GPR119RETDDB1CRBNSMN1; SMN2 | |
| SCHEMBL30931813 | 0.82 | GPR119 (0.76) | GPR119ME2ME1ME3CKS1B | |
| SCHEMBL1103897 | 0.82 | GPR119 (0.76) | GPR119ME2ME1ME3CKS1B | |
| SCHEMBL22581906 | 0.81 | GPR119 (0.60) | GPR119RETDDB1CRBNMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12325708-B2 | Adenosine 2 receptor antagonists | NEKTAR THERAPEUTICS (US) | 2025-06-10 | — | — | US | disclosed |
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS | 2022-07-28 | — | — | US | disclosed |
| WO-2020227156-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | NEKTAR THERAPEUTICS (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235056-A1 | ADENOSINE 2 RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | GPR119 70/4885RET 237/4885ME2 1300/4885 |
| US-12325708-B2 | Adenosine 2 receptor antagonists | ADORA2A, ADORA2B, ADORA3 | GPR119 70/4885RET 237/4885ME2 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.